Literature DB >> 12640223

Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations.

Michael Deuschle1, Bettina Hamann, Cornelia Meichel, Bertram Krumm, Florian Lederbogen, Anja Kniest, Michael Colla, Isabella Heuser.   

Abstract

With regard to the course of basal human hypothalamus-pituitary-adrenal (HPA) system activity, there is a lack of data for comparing different classes of antidepressants. Ninety-four patients were included in a study comparing standardized treatment with paroxetine (PAROX) and amitriptyline (AMI) after a drug-free period of at least 6 days. Saliva for measurement of cortisol concentrations was obtained daily at 0800, 1600, and 2200 during the 6 days of drug-free washout and 35 days of active treatment. The course of HPA system activity and psychopathology, as assessed by the Hamilton Depression Scale, was compared by means of repeated-measurement analyses of variance (ANOVA-rm). Only AMI responders-not PAROX responders or nonresponders to either antidepressant-had a significant decline in saliva cortisol concentrations. In hypercortisolemically depressed patients, treatment with AMI may be preferable to PAROX in order to lower HPA system activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640223     DOI: 10.1097/00004714-200304000-00014

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  15 in total

1.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

2.  The Mood, Mother, and Infant Study: Associations Between Maternal Mood in Pregnancy and Breastfeeding Outcome.

Authors:  Alison M Stuebe; Samantha Meltzer-Brody; Cathi Propper; Brenda Pearson; Pamela Beiler; Mala Elam; Cheryl Walker; Roger Mills-Koonce; Karen Grewen
Journal:  Breastfeed Med       Date:  2019-08-19       Impact factor: 1.817

Review 3.  Cognition in mania and depression: psychological models and clinical implications.

Authors:  Samuel R Chamberlain; Barbara J Sahakian
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 5.285

4.  A history of depression in women is associated with an altered GABAergic neuroactive steroid profile.

Authors:  Susan S Girdler; Monica Lindgren; Patrizia Porcu; David R Rubinow; Jacqueline L Johnson; A Leslie Morrow
Journal:  Psychoneuroendocrinology       Date:  2011-09-03       Impact factor: 4.905

5.  Effects of antidepressant drug therapy with or without physical exercise on inflammatory biomarkers in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Beatriz Monteiro Fernandes; Estêvão Scotti-Muzzi; Márcio Gerhardt Soeiro-de-Souza
Journal:  Eur J Clin Pharmacol       Date:  2021-10-27       Impact factor: 2.953

6.  Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk?

Authors:  C Barr Taylor; Ansgar Conrad; Frank H Wilhelm; Diane Strachowski; Anna Khaylis; Eric Neri; Janine Giese-Davis; Walton T Roth; John P Cooke; Helena Kraemer; David Spiegel
Journal:  J Psychiatr Res       Date:  2009-07-04       Impact factor: 4.791

7.  Cortisol reactivity to experimentally manipulated psychosocial stress in young adults at varied risk for depression.

Authors:  Matthew C Morris; Uma Rao; Lily Wang; Judy Garber
Journal:  Depress Anxiety       Date:  2013-04-19       Impact factor: 6.505

8.  Effect of paroxetine on physiological response to stress and smoking.

Authors:  Michael Kotlyar; Mustafa al'Absi; Paul Thuras; John P Vuchetich; David E Adson; April L Nowack; Dorothy K Hatsukami
Journal:  Psychosom Med       Date:  2013-03-15       Impact factor: 4.312

9.  A clinical study of the efficacy of a single session of individual exercise for depressive patients, assessed by the change in saliva free cortisol level.

Authors:  Megumi Ida; Itsurou Ida; Naoki Wada; Makoto Sohmiya; Masayuki Tazawa; Kenji Shirakura
Journal:  Biopsychosoc Med       Date:  2013-12-06

10.  Chronic escitalopram treatment attenuated the accelerated rapid eye movement sleep transitions after selective rapid eye movement sleep deprivation: a model-based analysis using Markov chains.

Authors:  Diána Kostyalik; Szilvia Vas; Zita Kátai; Tamás Kitka; István Gyertyán; Gyorgy Bagdy; László Tóthfalusi
Journal:  BMC Neurosci       Date:  2014-11-19       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.